Telix Pharmaceuticals (TLX) reported Q1 unaudited revenue Tuesday of about $186 million, up from $115 million a year earlier.
Two analysts polled by FactSet expected $145.3 million.
For 2025, the biotech company reaffirmed its previous revenue guidance of $770 million to $800 million.
Analysts polled by FactSet expect $770 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.